1046357-26-9

Upstream product

• 1046357-21-4 (S)-4-(nitrooxy)butyl 2-amino-3-(4-hydroxyphenyl)propanoate 
• 75-36-5 acetyl chloride 

Downstream Products

• 1046357-31-6 4-nitrooxy-butyl 2-acetamido-3-(4-((4-nitrophenoxy)carbonyloxy)phenyl)propanoate 
• 1207431-06-8 (9R,10S,11S,13S,16S,17R)-17-(2-((4-((S)-2-acetamido-3-(4-(nitrooxy)butoxy)-3-oxopropyl)phenoxy)carbonyloxy)acetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl 4-(nitrooxy)butanoate 

Relevant academic research and scientific papers

NEW NO-RELEASING STEROIDS FOR THE TREATMENT OF RETINA AND MACULA LUTEA DISEASES

The invention relates to compounds of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof (formula1) The compounds are useful for treating diabetic macular edema, diabetic retinopathy, macular degeneration, age- related macular degeneration and other diseases of retina and macula lutea.

NITRIC OXIDE RELEASING STEROIDS

The invention relates to nitrooxyderivative of corticosteroids of generalformula (I) and pharmaceutically acceptable salts or stereoisomers thereof wherein R is the corticosteroid residue of formula (II): wherein: R1 is OH, R2-CH3, or R1 and R2 are taken together to form a group of formula (III) R3 is C1 or F; R4 is H or F; wherein R1, R2, R3 and R4 can be linked to the correspondent carbon atoms of the steroidal structure in position β or β; with the proviso that: when R1 and R2 are the group of formula (III) then R3 is F and R4 is H or F; The compounds are useful in the treatment of respiratory diseases, inflammatory diseases, dermatological diseases and oculardiseases.